Currency in USD
Last close As at 24/03/2023
USD0.39
▲ 0.01 (2.63%)
Market capitalisation
USD6m
Research: Healthcare
InMed Pharmaceuticals’ (INM’s) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3m, all cannabichromene (CBC). As of January, it also began selling cannabicitran (CBT) to the health and wellness market. The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids and rounds out InMed’s manufacturing capabilities. INM continued advancing its drug development programs, including its ongoing 755-201-EB Phase II trial and preparing for an INM-088 FDA pre-investigational new drug meeting to treat glaucoma.
InMed Pharmaceuticals |
Generating commercial sales of CBC and CBT |
Financial update |
Pharma & biotech |
16 February 2022 |
Share price performance
Business description
Next events
Analyst
InMed Pharmaceuticals is a research client of Edison Investment Research Limited |
InMed Pharmaceuticals’ (INM’s) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3m, all cannabichromene (CBC). As of January, it also began selling cannabicitran (CBT) to the health and wellness market. The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids and rounds out InMed’s manufacturing capabilities. INM continued advancing its drug development programs, including its ongoing 755-201-EB Phase II trial and preparing for an INM-088 FDA pre-investigational new drug meeting to treat glaucoma.
Year end |
Revenue ($m) |
EBITDA* |
PBT* |
EPS |
DPS |
Yield |
06/20 |
0.0 |
(9.1) |
(9.0) |
(1.73) |
0.00 |
N/A |
06/21 |
0.0 |
(9.8) |
(10.3) |
(1.53) |
0.00 |
N/A |
06/22e |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
06/23e |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Note: *EBITDA, PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Q222: Results reflect BayMedica acquisition
InMed reported its first post-BayMedica acquisition (13 October 2021) results, with revenues of $0.3m from BayMedica’s sales. Net losses grew to $4.3m versus $1.9m in Q221, driven by increased R&D and G&A expenses from INM-755’s clinical trials, acquisition expenses and the inclusion of BayMedica’s operating results. With $11.3m of gross cash, management expects to have sufficient cash to fund opex and capex into Q123.
Extending focus to the health and wellness market
With the BayMedica acquisition, InMed has expanded its focus towards the health and wellness market, introducing B2B sales of CBT in January as well as planned product launches of CBDV and THCV in H222. Furthermore, InMed has several other high-value, rare cannabinoids in various stages of development. Management anticipates that this product pipeline will generate substantial revenue growth in the next several quarters, and to support this growth of wholesale B2B revenues, InMed announced the hiring of a VP of sales, Gerard P. Griffin III.
Notable advances in pharma drug development
InMed also announced several notable advances in its drug development program. Enrollment for the 755-201-EB trial (to treat Epidermolysis bullosa) began in December and management expects to complete it during CY22. Also in December, INM announced a peer-reviewed scientific article regarding using CBN to treat glaucoma. It continued preparing for its FDA meeting re: INM-088 and also filed an international patent application for using rare cannabinoids to treat neurodegenerative diseases such as Alzheimer’s, expanding its IP portfolio.
Valuation: Forecasts under review
Our forecasts are under review, and we will update our model and valuation to reflect the BayMedica acquisition in an upcoming Outlook note.
|
|
Research: Investment Companies
Gresham House Energy Storage Fund (GRID) invests in a diversified portfolio of utility-scale battery energy storage systems (BESS) in the UK and Ireland. It is the largest UK listed BESS fund and the largest operator in the market, and it is growing rapidly. GRID owns 17 operational projects with capacity totalling 425MW, which have delivered a good performance since inception. It also has eight projects (comprising a further 415MW) under construction and due to begin operating in 2022, and expects total capacity to exceed 1,500MW by 2024. BESS are a key part of the UK’s commitment to reach net zero carbon emissions by 2050. Demand for these units is projected to rise from 1.4GW today to an estimated 42GW by 2050, according to National Grid. We believe GRID’s asset valuation policy is conservative relative to its peers, providing scope for potential NAV uplift. GRID’s manager, Ben Guest, has the funding to deliver the current pipeline and in our view, it is possible that GRID may raise further funds in 2022 to drive growth in 2023 and beyond. The fund has a high dividend policy, currently paying a dividend of 7.0p per share.
Get access to the very latest content matched to your personal investment style.